Donald L. Trump
Roswell Park Cancer Institute
Buffalo
New York
Name/email consistency: high
- Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Trump, D.L., Payne, H., Miller, K., de Bono, J.S., Stephenson, J., Burris, H.A., Nathan, F., Taboada, M., Morris, T., Hubner, A. Prostate (2011)
- Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Trump, D.L., Deeb, K.K., Johnson, C.S. Cancer. J (2010)
- Vitamin D deficiency and insufficiency among patients with prostate cancer. Trump, D.L., Chadha, M.K., Sunga, A.Y., Fakih, M.G., Ashraf, U., Silliman, C.G., Hollis, B.W., Nesline, M.K., Tian, L., Tan, W., Johnson, C.S. BJU Int. (2009)
- Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Trump, D.L., Potter, D.M., Muindi, J., Brufsky, A., Johnson, C.S. Cancer (2006)
- Vitamin D compounds: clinical development as cancer therapy and prevention agents. Trump, D.L., Muindi, J., Fakih, M., Yu, W.D., Johnson, C.S. Anticancer Res. (2006)
- Anti-tumor activity of calcitriol: pre-clinical and clinical studies. Trump, D.L., Hershberger, P.A., Bernardi, R.J., Ahmed, S., Muindi, J., Fakih, M., Yu, W.D., Johnson, C.S. J. Steroid Biochem. Mol. Biol. (2004)
- Chemotherapy of prostate cancer: present and future. Trump, D., Lau, Y.K. Curr. Urol. Rep (2003)